1.Therapeutic effects of different treatments of hilar cholangiocarcinoma
Zhiqiang HAO ; Degang JI ; Zihui MENG ; Lei GUO ; Wei LI
Chinese Journal of Hepatobiliary Surgery 2017;23(8):517-520
Objective To analyze the clinical data of patients with hilar cholangiocarcinoma (HCCA),and to compare the therapeutic effects of different methods on treating these patients.Methods The clinical data of 101 patients with HCCA in China-Japan Union Hospital of Jilin University were analyzed.Results The overall 1-year and 2-year survival rates in the radical operation group were 95.5% and 40.9%,respectively.There was a significant difference between the radical operation group and the palliative resection group (P < 0.05).The overall 1-year and 2-year survival rates in the palliative resection group were 75.0% and 16.7%,respectively,which were much better than those in patients treated with PTCD,biliary stent on open abdominal biliary drainage (P < 0.05).There were no significant differences among the PTCD,biliary stent and open abdominal biliary drainage groups (P > 0.05).Conclusions Radical HCCA resection is still the best and the first choice treatment for patients with HCCA.The therapeutic effects of radical operation were much better than those of palliative resection,biliary stent,PTCD and open abdominal biliary drainage.
2.Relationship between pancreatic cancer and diabetes mellitus
Li TIAN ; Fanli ZENG ; Degang JI ; Zhanpeng WANG ; Wei LI ; Xuewen ZHANG
Chinese Journal of Hepatobiliary Surgery 2012;18(7):508-511
ObjectiveTo analyze the relationship between pancreatic cancer (PC) and diabetes mellitus (DM),and the clinical and pathological features of pancreatic cancer in patients with DM.MethodsFrom January,2008 to December,2010,151 patients with PC and 195 comparable patients without PC were enrolled in a case-control study to analyze the relationship between PC and DM.ResultsThe OR was 5.91 (95% CI 3.03-8.00,P<0.05) in PC patients with DM for less than 2 years,and 1.308 (95% CI 0.37-4.60,P>0.05) in patients with DM for 2 to 5 years,and 1.16(95% CI 0.44-3.19,P>0.05) for patients with DM for more than 5 years.There was no significant difference between PC patients with and without DM in gender,age,body-mass index (BMD,obstructive jaundice,tumour location and tumour metastases (P>0.05).ConclusionsThere was a significant correlation between PC and DM.De novo DM may be a clinical manifestation in patients with PC.PC patients with concurrent DM have no particular clinical and pathological features.
3.Correlation between M2BPGi level and the risk of hepatocellular carcinoma: a meta-analysis
Morun LIANG ; Yanshuo YE ; Degang JI ; Wei LI
Chinese Journal of Hepatobiliary Surgery 2022;28(12):936-942
Objective:To systematically review the correlation between serum Mac-2-binding protein glycosylation isomer (M2BPGi) level and hepatocellular carcinoma (HCC).Methods:The PubMed, Embase, Ovid, CBM (China Biology Medicine), Wanfang Databases were searched for studies on the correlation between serum M2BPGi level and HCC. After the selection process, 16 papers were included in this systematic review. A total of 7 810 patients were enrolled in the study, including 629 patients with HCC. The RevMan 5.2 software and R 4.1.2 software were used for the meta-analysis.Results:The elevated level of M2BPGi was significant positively associated with the risk of HCC( HR=2.28, 95% CI: 1.82-2.86, P<0.01). In Japan and Chinese groups, the elevated level of M2BPGi was significantly associated with an increased risk of HCC, with HR of 4.77 (95% CI: 2.73-8.32, P<0.01) and 2.04 (95% CI: 1.38-3.03, P<0.01), respectively. The elevated level of M2BPGi in three subgroups of people with untreated hepatitis C virus (HCV) infection, during treatment of hepatitis B virus (HBV) infection, and after HCV virological cure predicted an increased risk of HCC, with HR of 3.14 (95% CI: 2.19-4.50, P<0.01), 2.09 (95% CI: 1.36-3.22, P<0.01) and 5.07 (95% CI: 1.57-16.42, P<0.01), respectively. Conclusion:The elevated level of M2BPGi can indicate the increased risk of HCC, which can be used as one of the early warning indicators of HCC.
4. Neurocognitive profiles and related factors of subjective cognitive decline
Xiaojuan JIANG ; Zhiqiang WANG ; Degang WANG ; Wei FENG ; Pengpeng LI ; Li JI ; Jun GU ; Li TANG ; Hongyu YANG ; Zaohuo CHENG
Chinese Journal of Behavioral Medicine and Brain Science 2019;28(9):832-836
Objective:
To investigate the neurocognitive characteristics and related factors in the elderly with subjective cognitive decline.
Methods:
Among the 1 850 elderly volunteers aged over 50, 377 cognitive normal elderly (NC group), 234 subjective cognitive decline (SCD Group) and 291 patients with mild cognitive impairment (aMCI Group) were screened with the brief elderly cognitive screening questionnaire and the elderly rapid cognitive screening scale.They were all received clinical interview and examination and core neurocognitive test.
Results:
(1) There were statistically significant differences in the three groups on the age, education, occupation, HAMD, low density lipoprotein and blood pressure (